Fundz Deep Dive
Everything you need to win Acadia Pharmaceuticals — in one platform.
Who to reach, what to say, and why now on Acadia Pharmaceuticals — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Acadia Pharmaceuticals — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Acadia Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $150 Million
Contract Type
agreement
San DiegoDescription
Acadia Pharmaceuticals has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million. The PRV was granted in March 2023 following the approval by the U.S. Food and Drug Administration (FDA) of DAYBUE™ for the treatment of Rett syndrome. Acadia plans to invest the proceeds from the sale to support its commercial operations, R&D programs, and future business development.